Area riservata

Inserisci i tuoi dati di accesso. Se non li possiedi premi su "Registrati" per iniziare la procedura di creazione account. Attenzione: se sei già registrato in uno dei servizi on line di AccMed (www, fad, ASKit, KeyTrials, KeySlides, ASAP, …) puoi utilizzare i dati di accesso già in tuo possesso.

Una selezione degli ultimi articoli scientifici pubblicati su riviste specializzate da autori "Under 40".


Criscitiello C, Viale G, Curigliano G.

Breast 2019;44:128-134.

The immune system plays a dual role of host-protecting and tumor-promoting, as elegantly expressed by the 'cancer immunoediting' hypothesis. Although breast cancer has not been traditionally considered to be immunogenic, recently there is accumulating and solid evidence on the association between immune system and breast cancer.

Mio C, Gerratana L, Bolis M, Caponnetto F, Zanello A, Barbina M, Di Loreto C, Garattini E, Damante G, Puglisi F.

Int J Cancer. 2019; 144:755-766

Bromodomain and Extra-Terminal (BET) proteins are historically involved in regulating gene expression and BRD4 was recently found to be involved in DNA damage regulation.

Pelizzari G, Gerratana L, Basile D, Fanotto V, Bartoletti M, Liguori A, Fontanella C, Spazzapan S, Puglisi F.

Cancer Treat Rev. 2019 Jan;72:7-14

The post-neoadjuvant setting in early breast cancer represents an attractive scenario for adjuvant clinical trials, offering the opportunity to test new drugs or combinations in high-risk patients who did not achieve pathologic complete response after primary treatment.

De Laurentiis M, Bonfadini C, Lorusso V, Cilenti G, Di Rella F, Altavilla G, Otero M, Ardizzoi A, Marchetti P, Peverelli G, Amoroso D, Vecchio S, Fiorio E, Orecchia S.

Support Care Cancer 2018; 26:4021-4029

Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event with cancer chemotherapy, despite the availability of effective antiemetic agents.

Esposito A, Viale G, Criscitiello C, Curigliano G

Expert Rev Clin Pharmacol 2018. [Epub ahead of print]

Patients with early HER2-positive breast cancer (BC) benefit from HER2-targeted systemic therapy. The endorsed standard adjuvant treatment for patients with early HER2-positive breast cancer is chemotherapy plus trastuzumab administered for 1 year.

Poggio F, Lambertini M, Bighin C, Conte B, Blondeaux E, D'Alonzo A, Dellepiane C, Boccardo F, Del Mastro L.

ESMO Open 2018; 3(Suppl 1)

Breast cancer is still the most frequent cancer diagnosed in women aged ≤40 years and the primary cause of death in this age group. The management of these patients needs a dedicated approach involving a multidisciplinary team that takes into account their treatment and survivorship issues.

Trestini I, Carbognin L, Monteverdi S, Zanelli S, De Toma A, Bonaiuto C, Nortilli R, Fiorio E, Pilotto S, Di Maio M, Gasbarrini A, Scambia G, Tortora G, Bria E.

Crit Rev Oncol Hematol 2018;129:54-66

Breast cancer represents the most frequent cancer among women in Western countries. Although physicians and patients have witnessed a significant evolution in both treatment strategies and personalized medicine (the identification of featured patients' subsets such as HER2-driven disease), the identification of additional prognostic clinical predictors referring to patients' dietary habits represents a research area aiming to further improve the overall management of this disease.

Criscitiello C, Golshan M, Barry WT, Viale G, Wong S, Santangelo M, Curigliano G.

Eur J Cancer 2018; 97:1-6

We conducted a meta-analysis of randomised trials evaluating pathological complete response (pCR) and surgical outcomes after neoadjuvant systemic therapy (NST) in patients with early breast cancer (EBC).

Grazie al contributo di Novartis